The Board of Pharmacy has received notice of the following product recall:

Sandoz Inc. is recalling all quantities and lots within expiry of Ranitidine Hydrochloride Capsules in the US to the consumer level because of confirmed contamination with N-Nitrosodimethylamine (NDMA) above levels established by the FDA in batches of Sandoz Ranitidine Hydrochloride Capsules. To date, Sandoz has not received any reports of adverse events related to use of the product as part of this recall.

Product Name	NDC Number	Lot Nbr.	Expiration Date	Date of Manufacture
RANITIDINE 150mg Capsules 500 count	0781-2855-05	HD1862	4/30/2020	4/19/2017
RANITIDINE 150mg Capsules 500 count	0781-2855-05	HP9438	9/30/2020	9/5/2017
RANITIDINE 150mg Capsules 500 count	0781-2855-05	HP9439	9/30/2020	9/6/2017
RANITIDINE 150mg Capsules 500 count	0781-2855-05	HP9440	9/30/2020	9/5/2017
RANITIDINE 150mg Capsules 60 count	0781-2855-60	HC9266	4/30/2020	4/19/2017
RANITIDINE 150mg Capsules 60 count	0781-2855-60	HD1865	4/30/2020	4/19/2017
RANITIDINE 150mg Capsules 60 count	0781-2855-60	HP9441	9/30/2020	9/6/2017
RANITIDINE 150mg Capsules 60 count	0781-2855-60	JK7994	8/31/2021	8/7/2018
RANITIDINE 150mg Capsules 60 count	0781-2855-60	JK8659	8/31/2021	8/7/2018
RANITIDINE 300mg Capsules 30 count	0781-2865-31	HD8625	4/30/2020	4/27/2017
RANITIDINE 300mg Capsules 30 count	0781-2865-31	HD9275	4/30/2020	4/27/2017
RANITIDINE 300mg Capsules 30 count	0781-2865-31	HU2207	8/31/2020	8/24/2017
RANITIDINE 300mg Capsules 30 count	0781-2865-31	HX6676	3/31/2021	3/20/2018
RANITIDINE 300mg Capsules 30 count	0781-2865-31	HX6677	3/31/2021	3/20/2018

The affected Sandoz Ranitidine includes 30 count, 60 count and 500 count bottles in the following lots:

The Board of Pharmacy strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.